ArticleMolecular imaging and biology2026
Hybrid CNN-Transformer Framework for Molecular Imaging-based Early Alzheimer's Disease Detection.
Article in Molecular imaging and biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeHybrid convolutional neural network (CNN)-transformer models are increasingly proposed for molecular imaging, but scan-level leakage and targets derived from the same image-quantification pipeline can overstate performance. We tested whether an image-only hybrid model could classify florbetapir PET amyloid positivity under participant-disjoint validation. PROCEDURES: The Dallas Lifespan Brain Study contributed 551 longitudinal PET scans from 295 participants; 152 scans (27.6%) were amyloid-positive using the released global standardized uptake value ratio (SUVR) threshold of 1.09. Raw PET volumes were rigidly registered without label access and represented by 24 axial slices. CNN-GAP, slice-transformer, and age/sex baselines were evaluated using nested five-fold stratified group cross-validation. Calibration and operating thresholds were learned only within validation partitions, and 95% confidence intervals used 2,000 participant-cluster bootstrap resamples.
resultsThe hybrid achieved ROC-AUC 0.496 (95% CI 0.427-0.569), PR-AUC 0.274, balanced accuracy 0.490, and Matthews correlation coefficient -0.017. It did not outperform CNN-GAP (paired AUC difference -0.006, 95% CI -0.078 to 0.065) and performed below the age/sex baseline (AUC 0.690; hybrid-minus-baseline difference -0.194, 95% CI -0.287 to -0.100). Baseline-only and stable-label sensitivity analyses yielded hybrid AUCs of 0.529 and 0.502.
conclusionsRaw registered PET slices did not provide stable participant-generalizable classification of an SUVR-derived amyloid target. Participant-level separation, validated tracer quantification, demographic baselines, and external validation remain necessary before clinical interpretation.
Indexed as
Identifiers
42778810What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.